BioPlus Acquisition Corp.
BioPlus Acquisition Corp. Fundamental Analysis
BioPlus Acquisition Corp. (BIOSU) shows weak financial fundamentals with a PE ratio of 1249.89, profit margin of 0.00%, and ROE of 2.33%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BIOSU's fundamental strength across five key dimensions:
Efficiency Score
WeakBIOSU struggles to generate sufficient returns from assets.
Valuation Score
WeakBIOSU trades at a premium to fair value.
Growth Score
WeakBIOSU faces weak or negative growth trends.
Financial Health Score
ExcellentBIOSU maintains a strong and stable balance sheet.
Profitability Score
WeakBIOSU struggles to sustain strong margins.
Key Financial Metrics
Is BIOSU Expensive or Cheap?
P/E Ratio
BIOSU trades at 1249.89 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BIOSU's PEG of 12.50 indicates potential overvaluation.
Price to Book
The market values BioPlus Acquisition Corp. at 28.94 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -174.39 times EBITDA. This is generally considered low.
How Well Does BIOSU Make Money?
Net Profit Margin
For every $100 in sales, BioPlus Acquisition Corp. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.33 in profit for every $100 of shareholder equity.
ROA
BioPlus Acquisition Corp. generates $2.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
BIOSU converts -0.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1249.89
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
12.50
vs 25 benchmark
P/B Ratio
Price to book value ratio
28.94
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.04
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How BIOSU Stacks Against Its Sector Peers
| Metric | BIOSU Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1249.89 | 18.66 | Worse (Expensive) |
| ROE | 2.33% | 804.00% | Weak |
| Net Margin | 0.00% | 2258.00% | Weak |
| Debt/Equity | 0.02 | 1.03 | Strong (Low Leverage) |
| Current Ratio | 1.04 | 662.03 | Neutral |
| ROA | 2.17% | -24049.00% (disorted) | Weak |
BIOSU outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioPlus Acquisition Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical